Marktel, Sarah
Scaramuzza, Samantha
Cicalese, Maria Pia
Giglio, Fabio
Galimberti, Stefania
Lidonnici, Maria Rosa
Calbi, Valeria
Assanelli, Andrea
Bernardo, Maria Ester
Rossi, Claudia
Calabria, Andrea http://orcid.org/0000-0003-3515-3384
Milani, Raffaella
Gattillo, Salvatore
Benedicenti, Fabrizio
Spinozzi, Giulio
Aprile, Annamaria
Bergami, Alessandra
Casiraghi, Miriam
Consiglieri, Giulia
Masera, Nicoletta
D’Angelo, Emanuela
Mirra, Nadia
Origa, Raffaella
Tartaglione, Immacolata
Perrotta, Silverio
Winter, Robert
Coppola, Milena
Viarengo, Gianluca
Santoleri, Luca
Graziadei, Giovanna
Gabaldo, Michela
Valsecchi, Maria Grazia
Montini, Eugenio
Naldini, Luigi
Cappellini, Maria Domenica
Ciceri, Fabio
Aiuti, Alessandro
Ferrari, Giuliana http://orcid.org/0000-0003-0790-3133
Article History
Received: 25 July 2018
Accepted: 13 November 2018
First Online: 21 January 2019
Competing interests
: The San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) is a joint venture between the Telethon Foundation and Ospedale San Raffaele. The Telethon Foundation and Ospedale San Raffaele are entitled to receive milestone payments and royalties on commercialization of this therapy. A. Aiuti is the principal investigator of the SR-TIGET clinical trial of gene therapy for ß-thalassemia and S.M., M.P.C., F.G., V.C., M.D.C. and F.C. are co-investigators or sub-investigators. G.F. is the scientific director of the study. L.N. is an inventor on patents on lentiviral vector technology filed by the Salk Institute, Cell Genesys, Telethon Foundation and/or Ospedale San Raffaele, and may be entitled to receive some financial benefits from the licensing of such patents. All authors declare no other competing interests.